Clinical Advances in Chronic Obstructive Pulmonary Diseases in the Era of Precision Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 101

Special Issue Editors

Guest Editor
Pulmonologist, Private Sector, 42131 Trikala, Greece
Interests: asthma; COPD; pulmonology; lung disease

E-Mail Website
Guest Editor
1st Respiratory Department, Sotiria Chest Hospital, National and Kapodistrian University of Athens Medical School, 12462 Athens, Greece
Interests: spirometry; allergic diseases; pulmonology; lung diseases; asthma research; lung disease; chronic obstructive pulmonary disease; allergy

Special Issue Information

Dear Colleagues,

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. COPD is complex and heterogeneous with respect to its aetiology, clinical presentation, phenotypes, and biological mechanisms. To address this complexity in clinical practice, and to move further toward personalized and precision medicine, a strategy based on the identification and treatment of so-called "treatable traits" has been proposed. There is an urgent need to identify COPD patients at high risk for poor outcomes and to understand at a mechanistic level why certain individuals are at high risk. Genetics, omics, and network analysis have begun to be used to unravel the heterogeneity of COPD and diagnose people with particular pathobiologies. Treating COPD patients according to their unique pathophysiological abnormalities and identifying high-risk individuals will become much easier with the availability of larger data sets, more omics, and new analytical techniques. These methods hold significant potential for COPD risk assessment, early intervention, medication repurposing, and the creation of innovative treatment strategies. This Special Issue will address precision medicine approaches, which focus on understanding an individual's disease risk, and tailoring management based on pathobiology, environmental exposures, and psychosocial issues. Therefore, to move this field forward, we invite original research, perspectives, and state-of-the-art reviews on clinical advances in COPD.

Dr. Κonstantinos Bartziokas
Dr. Andriana I. Papaioannou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • personalized management
  • treatment
  • co-morbidities
  • COPD exacerbation
  • disease progression
  • mortality
  • pathogenesis
  • airway inflammation
  • biomarker

Published Papers

This special issue is now open for submission.
Back to TopTop